Healthcare Industry News: Huntington's Disease
News Release - August 23, 2007
Prestwick Pharmaceuticals, Inc. Strengthens Management Team with Appointment of Robert S. Radie as Chief Business OfficerWASHINGTON, Aug. 23 (HSMN NewsFeed) -- Prestwick Pharmaceuticals, Inc., a privately-held biotechnology company, today announced that it added Robert S. Radie to its senior management team as Executive Vice President and Chief Business Officer.
Mr. Radie joins Prestwick most recently from Morphotek, Inc., where he was Vice President of Project Management and Chief Business Officer, and helped lead the successful acquisition of Morphotek by Eisai earlier this year.
Mr. Radie will be responsible for Prestwick's commercial operations and business development activities that support its portfolio of drugs in development. Prestwick's portfolio of drugs in development includes its lead product candidate, tetrabenazine, a highly selective and reversible dopamine depletor in Phase 3 clinical trials for potential use as a treatment for chorea associated with Huntington's Disease.
"Bob strengthens our management team with over 22 years of experience in the pharmaceutical and biotechnology industry and a strong track record of business development and sales and marketing achievement," said George F. Horner, III, President and Chief Executive Officer of Prestwick. "He has guided strategic deals and acquisitions, built sales forces from the ground up and established commercial infrastructures to launch new products."
Prior to Morphotek, Mr. Radie worked with Mr. Horner as Senior Vice President of Strategic Projects and Planning at Vicuron Pharmaceuticals, Inc., where Mr. Radie was responsible for marketing and sales, corporate strategy and business development. In 2005 he played a key role in the acquisition of Vicuron by Pfizer for $1.9 billion.
Before joining Vicuron, Mr. Radie spent his professional career in positions of increasing responsibility at Eli Lilly and Company. During his tenure at Eli Lilly he managed several successful product launches and led national sales forces, most recently as the director of sales for Eli Lilly's critical care division. Mr. Radie oversaw the U.S. deployment for the critical care division, which included a team of 231 sales representatives and 23 district managers. Mr. Radie also contributed to the shaping of Eli Lilly's reimbursement strategy which was designed to ensure that hospital products gained timely formulary approval. Prior to that, as director of sales for Eli Lilly's diabetes top performing business unit in the northeast region, Mr. Radie launched three new products, including Actos® and Humalog Mix 75/25®, and led a significant expansion of that sales force. He also played an important role in the launch of Prozac® and Zyprexa®, Eli Lilly's two leading neuroscience drugs.
Prestwick is currently managing a portfolio of pipeline product candidates being studied for CNS conditions with significant unmet needs, including Huntington's Disease, Parkinson's disease, restless legs syndrome, schizophrenia, autism, Alzheimer's disease and sleep apnea.
Please go to http://www.prestwickpharma.com for more information.
Source: Prestwick Pharmaceuticals
Issuer of this News Release is solely responsible for its
Please address inquiries directly to the issuing company.